

UNIVERSITI TEKNOLOGI MARA

**ATHEROPROTECTIVE POTENTIAL
OF LACTIC ACID BACTERIA AND
THE UNDERLYING
CHOLESTEROL-LOWERING
MECHANISM(S)**

NUR SYAKILA BINTI ROHAWI

Thesis submitted in fulfillment
of the requirements for the degree of
Doctor of Philosophy
(Pharmacology)

Faculty of Pharmacy

December 2021

ABSTRACT

Current treatments and management against atherosclerosis rely predominantly on lipid lowering and diet modification, however it appears to be rather modest, often compromised by the lack of response in high-risk patients and adverse effects. This raises the possibility of using hypocholesterolaemic probiotics for atheroprotection. Lactic acid bacteria (LAB), the most common, non-pathogenic and safe probiotics, were reported to possess cholesterol-lowering effects. Nevertheless, the beneficial effects of LAB are believed to be strain-dependent and their mechanisms are not completely understood. As such, the present study aimed to identify a superior strain of LAB with excellent cholesterol lowering and atheroprotective properties as well as to elucidate the underlying mechanisms. The present study identified *Pediococcus pentosaceus* LAB6 and *Lactobacillus plantarum* LAB12 with promising cholesterol-lowering effects from a preliminary screening of 12 locally sourced lactic acid bacteria (LAB; 5 *lactobacilli* and 7 *pediococci*) using the new method of cholesterol quantification through high-performance thin layer chromatography (HPTLC). The LAB yielded strain-dependent cholesterol reducing activity in two different growth media (MRSC: broth containing cholesterol and MRSBC:broth containing cholesterol and bile). LAB6 (MRSC, 51.95% and MRSBC, 57.49%) and LAB12 (MRSC, 58.89%; MRSBC, 68.50%) emerged as the best cholesterol-reducing LAB. Both LAB assimilated fluorescently-tagged cholesterol at the outermost layer of cell membranes. The LAB also facilitated the deconjugation activity (LAB6:100% vs >38%; LAB12:100% vs >75% deconjugation) against glyco- and tauro-conjugated bile salts, respectively. Capitalising on these beneficial properties, this study went on to investigate the anti-atherosclerotic and atheroprotective potentials of LAB *in vitro* and *in vivo*, respectively. For the *in vitro* study, the sub-toxic concentration of 24h LAB-fermented cell-free supernatant against RAW264.7 and HUVEC were determined using the sulforhodamine B assay. The LAB-derived CFS was also assessed against the oxLDL-induced foam cell formation assays [i.e., lipid staining by Oil Red O stain, mitochondrial dysfunction using the mitochondrial membrane potential (MMP) assay and antioxidant assays (i.e., glutathione and superoxide dismutase). The effects of LAB6- and LAB12-derived CFS against oxLDL-induced endothelial dysfunction was explored in HUVEC on monocyte-endothelial adhesion and MMP assay. The LAB6- and LAB12-derived CFS not only significantly ($p<0.05$) reduced oxLDL uptake, reduced MMP depolarisation and increased antioxidant activity in oxLDL-induced RAW264.7 cells, but also reduced monocytes adhesion and prevented MMP depolarisation on oxLDL-induced endothelial dysfunction. For the *in vivo* study, the atheroprotective properties of freeze-dried LAB12 (LAB12-FD) was explored using C57BL/6J mice fed with high-fat diet for 20 weeks. Daily consumption of LAB12-FD significantly reduced total cholesterol content in the livers, reduced fatty streak formation and infiltration of macrophages in the aortas, as well as improved intestinal barrier (i.e., reduced serum lipopolysaccharide content and urine lactulose mannitol ratio) of C57BL/6J mice. Altogether, the present findings strongly support the possibility of using LAB12 as a dietary supplement for prevention of hypercholesterolaemia and atherosclerosis. The current data also provides important insights into the complementary use of LAB in management of metabolic diseases.

ACKNOWLEDGEMENT

In the name of Allah, the Most Gracious and the Most Merciful. Alhamdulillah, all praises to Allah for His blessings, strength and patience that had enabled me to complete this thesis. First and foremost, I would like to express my sincere gratitude to my main supervisor, Prof. Dr. Kalavathy Ramasamy, for the precious opportunity to be involved in this important project. I am grateful for her trust, supervision, motivation, encouragement and sharing of knowledge throughout the course of this study. My sincere appreciation also goes to my co-supervisor, Assoc. Prof. Dr. Lim Siong Meng, for his constant help, constructive comments and careful reading of my write-up. The present work would not have been possible without both my supervisors' guidance and support. Special thanks from me to Prof. Dr. Snenaza Agatonovic Kustrin (Sechenov First Moscow State Medical University, Russia), Dr. Lim Fei Tieng (Hi-Tech Instrument Sdn Bhd), Dr. Hasseri Halim (Faculty of Pharmacy, UiTM), Assoc. Prof. Dato' Dr. Vellayan Subramaniam (Faculty of Pharmacy, UiTM), and staffs at LAFAM, Dr. Zolkapli Bin Eshak and Madam Nor Hayati Binti Monzai (Imaging Centre, UiTM) for their timely advice, sharing information and generous help at different stages of my PhD project.

I am really thankful for the financial support by the Ministry of Higher Education Malaysia and the Universiti Teknologi MARA (UiTM). I acknowledge receipt of funding under the Long Term Research Grant Scheme [600-RMI/LRGS 5/3 (2/2012)], *Geran Insentif Penyelidikan* (GIP) [600-IRMI/MyRA 5/3/GIP (046/2017)], 600-IRMI 5/3/GIP (089/2018), Fundamental Research Grant Scheme [600-IRMI/FRGS 5/3 (317/2019)] and UiTM Postgraduate Assistance Scheme (UPTA). I wish to give a shout-out to all members of the Collaborative Drug Discovery Research (CDDR) Laboratory, in particular Dr. Muhamad Fareez, Dr. Muhammad Zaki, Muhammad Zaki, Siti Hajar, Fatin Umirah, Dr. Syamimi, Dr. Yuganthini, Umi Khalsom, Naemah, Faedah, and Muhammad Syukri for all their assistance, kindness, cooperation and moral support. I cherish our friendship and all wonderful memories we had together. I am also thankful for the support and assistance from staffs and members of the Pharmacology and Toxicology Laboratory, the BRAIN Research Laboratory as well as all post-graduate students of the Faculty of Pharmacy, UiTM. I would also like to thank the dean, Assoc. Prof. Dr. Shariza Sahudin, lecturers, technical and supporting staffs of the Faculty of Pharmacy, UiTM for their direct and indirect contributions over the course of my postgraduate candidature.

Last but not least, I wish to express my deepest gratitude to my beloved husband (Mr Muhamad Azim Bin Azmi), parents (Mr Rohawi Bin Hassim and Madam Makhani Binti Ahmad), sisters (Ezatul Farita and Intan Nur Farahin) and brother (Muhammad Nur Ezzat), for their endless love, unceasing prayers and constant encouragement. My family members have always stood by me through good and bad times. To those whose names are not mentioned here, but has contributed to this research in one way or the other, your kindness meant a lot to me. Thank you very much.

TABLE OF CONTENTS

	Page
CONFIRMATION BY PANEL OF EXAMINERS	ii
AUTHOR'S DECLARATION	iii
ABSTRACT	iv
ACKNOWLEDGEMENT	i
TABLE OF CONTENTS	ii
LIST OF TABLES	vii
LIST OF FIGURES	x
LIST OF ABBREVIATIONS	xiv
LIST OF UNITS	xxii
CHAPTER ONE INTRODUCTION	1
1.1 Research Background	1
1.2 Problem Statement	3
1.3 Objectives	5
1.4 Significance of the study	6
CHAPTER TWO LITERATURE REVIEW	7
2.1 Atherosclerosis	7
2.1.1 Overview	7
2.1.2 Epidemiology	7
2.1.3 Risk Factors	10
2.1.4 Pathophysiology	13
2.1.5 Therapeutic and Lifestyle Intervention	22
2.1.6 Diet-Induced Dysbiosis	28
2.2 Probiotics Improved Dysbiosis: Potential Atheroprotection	32
2.2.1 Overview	32
2.2.2 Probiotics Reverse Dysbiosis in Atherosclerosis	36

2.2.3	Cholesterol-lowering Properties of Probiotics <i>In Vitro</i>	39
2.2.4	Hypocholesterolaemic Properties of Probiotics <i>In Vivo</i>	44
2.2.5	Hypocholesterolaemic Properties of Probiotics: Clinical Studies	51
2.2.6	The Effects of Probiotics against Atherosclerotic Parameters	57
CHAPTER THREE RESEARCH METHODOLOGY		69
3.1	Introduction	69
3.2	Materials	72
3.2.1	<i>In Vitro</i> Assessment of Pediococci- and Lactobacilli-Induced Cholesterol-Lowering Effects Using Digitally Enhanced HPTLC and Confocal Microscopy	72
3.2.2	A New HPTLC Method for Determination of Pediococci- and Lactobacilli-Induced Bile Salt Deconjugation	73
3.2.3	Anti-Atherosclerotic Effects of CFS Fermented by <i>P. pentosaceus</i> LAB6 and <i>L. plantarum</i> LAB12 <i>In Vitro</i>	74
3.2.4	Hypocholesterolaemic and Atheroprotective Effects of <i>L. plantarum</i> LAB12 in HFD-Induced C57BL/6J Mice	76
3.3	Methodology	81
3.3.1	<i>In Vitro</i> Assessment of Pediococci- and Lactobacilli-Induced Cholesterol-Lowering Effects Using Digitally Enhanced HPTLC and Confocal Microscopy	81
3.3.2	A New HPTLC Method for Determination of Pediococci- and Lactobacilli-Induced Bile Salt Deconjugation	89
3.3.3	Anti-Atherosclerotic Effects of CFS Produced by <i>P. pentosaceus</i> LAB6 and <i>L. plantarum</i> LAB12 <i>In Vitro</i>	94
3.3.4	Hypocholesterolaemic and Atheroprotective Effects of <i>L. plantarum</i> LAB12 in HFD-Induced C57BL/6J Mice	104
3.3.5	<i>In Vivo</i> Study of the Atheroprotective potential of LAB12	105
CHAPTER FOUR RESULTS		115
4.1	Introduction	115